VB10.NEO + bempegaldesleukin

**VB10.NEO + bempegaldesleukin** is a combination of two investigational immunotherapy products for cancer treatment. **VB10.NEO** is a personalized DNA cancer vaccine that aims to stimulate T cell responses against patient-specific neoantigens, whereas **bempegaldesleukin** is a pegylated interleukin-2 (IL-2) cytokine prodrug designed to selectively expand CD8+ effector T cells and natural killer (NK) cells in the tumor microenvironment, thereby enhancing antitumor activity. The combination is being studied primarily in oncology settings where robust immune activation is desired, leveraging the vaccine-induced T cells (from VB10.NEO) and their expansion/activation (by bempegaldesleukin). The principal developers are Nykode Therapeutics (for VB10.NEO) and Nektar Therapeutics (for bempegaldesleukin), with clinical development focusing on various solid tumors.